Articles

The results of the current phase 1b/2 study showed that the combination of azacitidine plus lirilumab was well-tolerated in heavily pretreated patients with relapsed acute myeloid leukemia (AML) and poor-risk disease features. Read More ›

An analysis of response and survival outcomes from the phase 1/2 AG221-C-001 study showed that continued treatment with enasidenib resulted in improved survival and response times in patients with mutant-IDH2 relapsed or refractory (R/R) acute myeloid leukemia (AML). Read More ›

A phase 1 dose-escalation study of FLX925, a dual FLT3 and CDK4/6 inhibitor, showed modest antileukemic activity in adult patients with relapsed or refractory acute myeloid leukemia (AML). Read More ›

Combination treatment with nivolumab plus azacitidine produced encouraging response rates in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with poor-risk features, and in elderly patients as frontline therapy. Read More ›

In a 1-year follow-up of the ZUMA-1 study, axicabtagene ciloleucel (axi-cel; anti-CD19 CAR T) demonstrated significant clinical benefit with manageable adverse events in patients with refractory, aggressive non-Hodgkin lymphoma (NHL) and no curative treatment options, but loss of CD19 and gain of PD-L1 expression in tumors were identified as possible mechanisms of resistance following axi-cel treatment. Read More ›

Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP). Read More ›

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles. Read More ›

These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months. Read More ›

This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 10⁹/L from week 12 onward and no new safety signals observed during the study period. Read More ›